rs151337641
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 2P and 3B. PM2BP4_ModerateBS1_Supporting
The NM_000081.4(LYST):c.5033T>C(p.Val1678Ala) variant causes a missense change. The variant allele was found at a frequency of 0.000154 in 1,607,234 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000081.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LYST | ENST00000389793.7 | c.5033T>C | p.Val1678Ala | missense_variant | Exon 16 of 53 | 5 | NM_000081.4 | ENSP00000374443.2 | ||
LYST | ENST00000489585.5 | n.5033T>C | non_coding_transcript_exon_variant | Exon 16 of 23 | 1 | ENSP00000513166.1 | ||||
LYST | ENST00000697178.1 | n.*457T>C | non_coding_transcript_exon_variant | Exon 15 of 52 | ENSP00000513163.1 | |||||
LYST | ENST00000697178.1 | n.*457T>C | 3_prime_UTR_variant | Exon 15 of 52 | ENSP00000513163.1 |
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 152192Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.0000681 AC: 17AN: 249646Hom.: 0 AF XY: 0.0000741 AC XY: 10AN XY: 134976
GnomAD4 exome AF: 0.000152 AC: 221AN: 1455042Hom.: 0 Cov.: 28 AF XY: 0.000151 AC XY: 109AN XY: 724132
GnomAD4 genome AF: 0.000171 AC: 26AN: 152192Hom.: 1 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74348
ClinVar
Submissions by phenotype
Chédiak-Higashi syndrome Uncertain:1Other:1
Variant interpreted as Uncertain significance and reported on 03-07-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 1678 of the LYST protein (p.Val1678Ala). This variant is present in population databases (rs151337641, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with LYST-related conditions. ClinVar contains an entry for this variant (Variation ID: 454486). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt LYST protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not specified Uncertain:1
Variant summary: LYST c.5033T>C (p.Val1678Ala) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.8e-05 in 249646 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in LYST causing Chediak-Higashi Syndrome (6.8e-05 vs 0.0011), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.5033T>C in individuals affected with Chediak-Higashi Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 454486). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Autoinflammatory syndrome Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at